Aptinyx

Aptinyx Current Liabilities

Delisted

The Current Liabilities of Aptinyx (APTX) as of Oct 23, 2026 is 11.09 M USD. In the previous year, Current Liabilities was 10.39 M USD — a change of 6.79% (higher).

Current Liabilities

11.09 MUSD

YoY

6.79%

Last updated:

Current Liabilities of Aptinyx is 2022 11.09 M USD. Current Liabilities of Aptinyx was 2021 10.39 M USD. It decreases by 6.79% higher compared to the previous year.

The Aptinyx Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2016
7.35 M USD
Jan 1, 2017
6.57 M USD
Jan 1, 2018
9.49 M USD
Jan 1, 2019
7.90 M USD
Jan 1, 2020
7.68 M USD
Jan 1, 2021
10.39 M USD
Jan 1, 2022
11.09 M USD
The Aptinyx Current Liabilities history
YEARCurrent LiabilitiesYoY
11.09 MUSD+6.79%
10.39 MUSD+35.18%
7.68 MUSD-2.70%
7.90 MUSD-16.75%
9.49 MUSD+44.32%
6.57 MUSD-10.55%
7.35 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptinyx Stock analysis

What does Aptinyx do? Aptinyx Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of neurological diseases. The company was founded in 2015 in Evanston, Illinois, USA, and has since achieved an impressive track record in researching and developing innovative therapies. The history of Aptinyx Inc begins with a group of experienced scientists and researchers who came together to push the boundaries of neuroscience research and discover new treatment options for people with brain disorders. The company is based on the belief that the human brain is a fascinating and complex entity that still holds many secrets. The company is committed to improving human well-being through innovative neurotherapeutic products and services. Aptinyx Inc's business model focuses on the research, development, and commercialization of novel therapeutic treatments for neurological diseases. The company closely collaborates with leading academic institutions and facilities to leverage the best research findings and methods. The company has a strong scientific foundation led by an experienced team of researchers and developers working on innovative biomarker and therapy strategies. Aptinyx Inc has focused on the development of neuromodulators and neuroprotectants to treat neurological diseases, including pain disorders, peripheral neuropathies, neuropathic pain, Parkinson's disease, post-traumatic stress disorder (PTSD), and other central nervous system disorders. Aptinyx Inc's products are based on a comprehensive understanding of the fundamentals of the nervous system and how it functions. The company offers a variety of products and services, including novel therapeutics for the treatment of pain, neuropathy, and other neurological diseases. These products are based on the utilization of Aptinyx's proprietary technologies to selectively modulate specific cell types and signaling pathways in the nervous system. The products and services of Aptinyx Inc have been regulated by leading health authorities in the US and Europe. Aptinyx Inc has two main divisions of products: the first focus is on the development of neuromodulators that specifically alleviate pain and modulate the brain. The second focus is on the development of neuroprotectants that help protect neurons and reduce inflammation in the nervous system. These two divisions are closely interconnected as they are based on a common platform grounded in the exploration of novel biomarkers and therapeutic targets. The products of Aptinyx Inc are designed for both pain relief and improvement of neural functions. Additionally, these products aim to enhance patient experience and quality of life. The company consistently collaborates with potential partners and experts to develop products tailored to the needs of patients and healthcare providers. Overall, Aptinyx Inc has revolutionized the world of neuroscience by exploring and developing innovative solutions for neurological diseases. The company has achieved an impressive track record by utilizing its scientific expertise and groundbreaking technologies to set new trends in neuroscience research and therapeutics. In summary, Aptinyx Inc has developed a unique approach to the development of neuromodulators and neuroprotectants based on a deep understanding of the structure and function of the nervous system. The products and services of the company have the potential to play a significant role in improving the quality of life for patients with neurological diseases. Aptinyx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptinyx stock

Current Liabilities of Aptinyx is 11.09 M USD in 2022.

Current Liabilities of Aptinyx changed from 10.39 M USD to 11.09 M USD, representing a 6.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Aptinyx since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Aptinyx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aptinyx

All Key Metrics — Aptinyx